GI Innovation, Inc. Stock: price and insider trades · South Korea

GI Innovation, Inc. is a Health Care company. Its directors and officers file their transactions with DART (FSS). The last twelve months, up to 5 November 2026, brought 47 filings signed by 19 insiders.

On the market, 18 insiders bought (39 purchases totalling €273k) while 2 insiders sold (7 sales totalling €96.8M). The totals exclude 37 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 9 board members, 7 senior executives and 2 chief executives among the declarants. The largest single trade was a sale of €95.8M by 장명호, published on 3 April 2026, equal to 29.7% of the market capitalisation.

For context, the typical company on the same exchange (median of 2,656 companies) published 7 filings over the same period, against 47 filings here. Our records for GI Innovation, Inc. go back to 2023, with 79 purchases and 37 sales on the open market in total.

The data flag 5 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 10 August 2026, 91 days ago. Typically, a trade is published a median of 10 days after it takes place. That lag is the time during which only the insider knows about the trade.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.